Ivermectin

Search ⌘K Suggest Edit Sign in Chemical and Pharmacological Properties Established Human Medical Uses Veterinary Applications Safety and Adverse Effects History of Discovery and Development Emerging Research Directions COVID-19 Controversy Societal, Economic, and Regulatory Aspects References Fact-checked by Grok 4 months ago Ivermectin Ivermectin is a semi-synthetic anthelmintic drug derived from avermectins, a class of macrocyclic lactones produced by the soil bacterium Streptomyces avermitilis. [1] Discovered in the 1970s through collaborative efforts led by Satoshi Ōmura at the Kitasato Institute in Japan and William C. Campbell at Merck & Co., it targets invertebrate glutamate-gated chloride channels, inducing paralysis and death in parasites by hyperpolarizing nerve and muscle cells. [2] [3] The compound's development earned Ōmura and Campbell the 2015 Nobel Prize in Physiology or Medicine for discoveries revolutionizing treatments for parasitic infections like river blindness (onchocerciasis) and lymphatic filariasis. [4] Approved by the U.S. Food and Drug Administration in 1987 for human use and included on the World Health Organization Model List of Essential Medicines, ivermectin treats intestinal strongyloidiasis and onchocerciasis at specific oral doses, with topical formulations addressing head lice and rosacea. [5] [6] [7] Widely employed in veterinary medicine for heartworm prevention and livestock parasite control, its mass administration programs, including Merck's donation of over 3.7 billion doses via the Mectizan Donation Program since 1987, have drastically reduced blindness and skin disease in endemic regions, averting an estimated 4 million cases of river blindness annually. [1] Its safety profile at approved doses is favorable, with rare serious adverse effects primarily linked to high parasite loads causing Mazzotti reactions. [3] Ivermectin gained prominence during the COVID-19 pandemic as a proposed repurposed treatment, with in vitro studies demonstrating inhibition of SARS-CoV-2 replication at high concentrations and some early observational data suggesting reduced viral loads or mortality. Similar in vitro antiviral effects have been reported against other RNA viruses, including influenza viruses, through mechanisms such as inhibition of nuclear import via importin α/β1.[8] However, multiple randomized controlled trials and meta-analyses of higher-quality evidence, including Cochrane reviews, found no significant reductions in hospitalization, mechanical ventilation, or mortality risks among treated patients with COVID-19, leading regulatory bodies like the FDA and EMA to advise against its use outside clinical trials due to insufficient efficacy and potential for misuse. There is no clinical trial evidence supporting ivermectin's use for prevention or treatment of influenza in humans, and major health authorities such as the CDC and FDA do not recommend it for this purpose due to lack of supporting clinical data. Conflicting meta-analyses highlighting benefits have been criticized for including flawed or retracted studies, underscoring challenges in interpreting observational data amid institutional pressures and the drug's low cost, which may have influenced rapid dismissal despite initial mechanistic plausibility. Ongoing research explores its broader antiparasitic and potential anti-inflammatory roles, but empirical data affirm its primary value in controlling neglected tropical diseases rather than viral infections. [9] [10] [11] [12] [13] Chemical and Pharmacological Properties Chemical Structure and Synthesis Ivermectin is a semi-synthetic derivative of the naturally occurring avermectins, specifically comprising a mixture of at least 80% 22,23-dihydroavermectin B1a and not more than 20% 22,23-dihydroavermectin B1b.[2] The molecular formula of the major component, 22,23-dihydroavermectin B1a, is C48H74O14, with a molar mass of 875.1 g/mol.[14] Its structure features a 16-membered macrocyclic lactone ring fused to an oxahydrindene system and a spiroketal moiety, with a disaccharide (oleandrose) attached at the C-13 position and specific stereocenters contributing to its biological activity.[14] The B1a and B1b homologues differ in the substituent at C-25, where B1a has a sec-butyl group and B1b a isopropyl group.[2] The synthesis of ivermectin involves the fermentation of the soil bacterium Streptomyces avermitilis to produce the avermectin complex, followed by isolation of the B1 fraction (primarily avermectin B1a and B1b).[3] This is then subjected to selective catalytic hydrogenation to reduce the 22,23-double bond, yielding the dihydro derivatives that constitute ivermectin.[15] This semi-synthetic process, developed by Merck researchers in the late 1970s, enhances the compound's stability and efficacy compared to the parent avermectins.[3] Commercial production maintains the specified ratio of components through optimized fermentation and purification steps, ensuring pharmaceutical-grade purity.[2] Mechanism of Action Ivermectin selectively binds with high affinity to glutamate-gated chloride channels (GluCl) in the nerve and muscle cells of invertebrates, including nematodes and arthropods.[2] This binding increases chloride ion permeability, causing membrane hyperpolarization, disruption of normal neurotransmission, paralysis, and death of the target parasites.[3] GluCl channels, absent in vertebrates, represent the primary molecular target responsible for ivermectin's potent antiparasitic activity at therapeutic doses.[16] At higher concentrations, ivermectin potentiates the effects of gamma-aminobutyric acid (GABA) on GABA-gated chloride channels and glycine on glycine-gated channels in invertebrates, further enhancing inhibitory neurotransmission and contributing to paralysis.[2] These interactions amplify chloride influx but are secondary to GluCl activation, as evidenced by structure-activity studies and receptor binding assays.[17] The drug's selectivity for invertebrates stems from the lack of GluCl channels in mammals and ivermectin's limited ability to cross the blood-brain barrier, minimizing effects on vertebrate GABA or glycine receptors despite some binding affinity.[3] Electrophysiological studies confirm that ivermectin opens GluCl channels in a non-competitive manner with glutamate, leading to sustained channel activation and ion flux independent of the agonist at saturating concentrations.[17] This mechanism underlies ivermectin's efficacy against a broad spectrum of helminths and ectoparasites while maintaining a favorable safety profile in humans and other vertebrates.[2] Pharmacokinetics Ivermectin exhibits moderate oral bioavailability in humans, with plasma concentrations proportional to dose. Following a single 12 mg (165 mcg/kg) oral dose in fasting healthy volunteers, mean peak plasma concentrations of the major component H₂B₁a reach approximately 46.6 ng/mL at about 4 hours post-administration.[18] Systemic exposure increases approximately 2.5-fold when taken with a high-fat meal compared to fasting conditions, due to enhanced absorption.[18] The alcoholic solution formulation yields roughly twice the systemic availability of tablet or capsule forms, with time to peak concentration (T_max) ranging from 3.4 to 5.6 hours across formulations.[19] While peak plasma concentrations occur around 4-5 hours post-dose, ivermectin's antiparasitic effects begin within hours (often 4-24 hours) as it binds to parasite channels causing paralysis and death. Noticeable clinical improvement in symptoms generally occurs within 1 to 7 days across indications, though full clearance may take weeks and symptom persistence (e.g., due to immune response to dead parasites) is common initially. Distribution of ivermectin is extensive, reflecting its high lipid solubility, with a volume of distribution of 3–3.5 L/kg.[2] It binds strongly to plasma proteins at 93%.[2] The drug accumulates in tissues such as fat and skin but does not readily cross the blood-brain barrier in humans due to intact P-glycoprotein efflux transport.[18] Metabolism occurs primarily in the liver via cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP2D6 and CYP2E1, yielding at least 10 metabolites through hydroxylation and demethylation.[18] [19] Excretion is predominantly fecal, with ivermectin and its metabolites eliminated almost exclusively via feces over an estimated 12 days and less than 1% recovered in urine.[2] The plasma elimination half-life is approximately 18 hours following oral dosing.[18] Clearance ranges from 3.1 to 10.6 L/kg/day, potentially influenced by gender, with lower values observed in males.[19] Pharmaceutical Formulations Ivermectin is the active ingredient in medications like Stromectol (oral tablets) and various generic versions. Formulations vary by manufacturer, brand, and route of administration (oral tablets, topical cream, lotion, etc.). For the most common human oral formulation (Stromectol 3 mg tablets by Merck): Active ingredient: ivermectin 3 mg per tablet Inactive ingredients/excipients: microcrystalline cellulose, pregelatinized starch, magnesium stearate, butylated hydroxyanisole (BHA), and anhydrous citric acid.[18] These tablets are film-coated and do not contain lactose. Generic ivermectin tablets may have slightly different excipients depending on the manufacturer, but the active ingredient remains ivermectin. === Topical formulations === Ivermectin is available in two main topical forms for human use: '''0.5% lotion (Sklice and generic equivalents)''': Approved by the FDA for the topical treatment of head lice infestations in patients 6 months of age and older. It has been available over-the-counter (OTC) in the United States since the FDA's Rx-to-OTC switch in 2020. The lotion is applied as a single-use treatment to dry hair and scalp, left on for 10 minutes, then rinsed off with water. It kills lice by disrupting their nerves and muscles and has some ovicidal activity, often eliminating the need for nit combing. A second treatment is not typically required, but if live lice persist after 7-10 days, consult a healthcare provider. It is for external use only and should not be used near eyes, mouth, or other mucous membranes. '''1% cream (Soolantra)''': A prescription medication used to treat inflammatory lesions of rosacea by reducing inflammation and possibly targeting Demodex mites. It is applied once daily to affected facial areas. These topical forms differ from oral ivermectin, which is used for systemic parasitic infections. Established Human Medical Uses Treatment of Helminth Infections Ivermectin serves as the primary chemotherapeutic agent for onchocerciasis (river blindness), caused by Onchocerca volvulus, where a single oral dose of 150 μg/kg, taken on an empty stomach with water, rapidly kills microfilariae in the skin and eyes, alleviating pruritus, dermatitis, and visual impairment while suppressing microfiladermia for 4–6 months.[20][21][18] It does not eradicate adult worms, necessitating repeated dosing annually or semi-annually in mass drug administration (MDA) programs to achieve at least 80% therapeutic coverage over 12–15 years for transmission elimination, as recommended by the World Health Organization (WHO).[22][23] Since 1987, over 4 billion doses have been distributed through the Mectizan Donation Program, substantially reducing prevalence in endemic African and Latin American regions.[21] For strongyloidiasis due to Strongyloides stercoralis, ivermectin is the preferred treatment, administered as a single oral dose of 200 μg/kg, taken on an empty stomach with water, in immunocompetent adults (FDA-recommended regimen for uncomplicated strongyloidiasis, though some guidelines suggest two daily doses), yielding cure rates of approximately 90% in uncomplicated chronic infections based on stool examination follow-up. A single dose achieves high initial efficacy but may require additional rounds in hyperinfection cases or immunocompromised patients to eliminate larval stages and prevent autoinfection; albendazole serves as an alternative but with lower parasitological cure rates.[24][25][18] In onchocerciasis, ivermectin rapidly reduces dermal microfilarial loads: approximately 78% reduction by day 2, 90% by day 3, 92–95% by days 7–8, and ~98% by 14–60 days post-dose. Symptom relief (e.g., pruritus, dermatitis) often begins within days but may include transient worsening due to Mazzotti reaction from dying parasites. For strongyloidiasis, ivermectin begins killing intestinal nematodes within hours to a few days, with digestive symptoms typically improving within a few days to 1 week and stool clearance over 1–2 weeks; repeat treatment may be needed in some cases. In lymphatic filariasis caused by Wuchereria bancrofti and related species, ivermectin functions as a microfilaricide in WHO-recommended MDA strategies, typically combined with albendazole (400 mg) and diethylcarbamazine (6 mg/kg) in a single-dose triple therapy that clears >90% of microfilariae for up to 2 years, outperforming dual-drug regimens in reducing transmission potential.[26][27] In loiasis-coendemic areas, ivermectin plus albendazole is used to avoid severe encephalopathy risks from diethylcarbamazine; however, it spares adult filarial worms, requiring sustained annual or biannual dosing for elimination.[26][28] Strongyloidiasis (FDA-approved indication) The recommended dosage is a single oral dose of 200 μg/kg body weight, taken on an empty stomach with water. In general, additional doses are not necessary, but follow-up stool examinations should verify eradication. For immunocompromised patients, repeated or suppressive therapy may be required. Dosage guidelines (3 mg tablets): 15–24 kg: 1 tablet (3 mg) 25–35 kg: 2 tablets (6 mg) 36–50 kg: 3 tablets (9 mg) 51–65 kg: 4 tablets (12 mg) 66–79 kg: 5 tablets (15 mg) ≥80 kg: 200 μg/kg (calculate exact) Onchocerciasis (FDA-approved indication) The recommended dosage is a single oral dose of 150 μg/kg body weight, taken on an empty stomach with water. Treatment may be repeated every 3–12 months, or every 6 months in cases with heavy ocular involvement. Dosage guidelines (3 mg tablets): 15–25 kg: 1 tablet (3 mg) 26–44 kg: 2 tablets (6 mg) 45–64 kg: 3 tablets (9 mg) 65–84 kg: 4 tablets (12 mg) ≥85 kg: 150 μg/kg (calculate exact) These tables are derived from the FDA-approved Stromectol prescribing information and facilitate practical administration. Ivermectin exhibits limited standalone efficacy against common soil-transmitted helminths (STH) like Ascaris lumbricoides and hookworms, where benzimidazoles (albendazole or mebendazole) remain first-line due to broader spectrum and higher egg reduction rates >95%.[29] It shows moderate activity against Trichuris trichiura, with meta-analyses of MDA indicating 50–70% prevalence reductions when added to standard regimens, though not sufficient for monotherapy elimination in high-burden settings.[30][31] U.S. Food and Drug Administration approval extends to strongyloidiasis and onchocerciasis, with off-label or investigational use for other helminths guided by regional guidelines.[24][20] Despite its limited spectrum—primarily effective against certain nematodes and largely ineffective against protozoan parasites, cestodes (tapeworms), or trematodes (flukes)—ivermectin's popularity as a parasitic treatment arises from its proven public health successes in onchocerciasis and strongyloidiasis control, facilitated by safe single-dose efficacy and the Mectizan Donation Program's distribution of billions of doses, earning it "wonder drug" status and recognition via the 2015 Nobel Prize in Physiology or Medicine for its discoverers.[3] Its extensive veterinary applications against diverse parasites further contribute to perceptions of versatility. Off-label use for broad intestinal "parasite cleanses" or detox, promoted in alternative health trends and social media, often overgeneralizes these targeted successes despite lacking evidence for most human intestinal parasites beyond approved nematode indications.[32] Treatment of Ectoparasites Ivermectin is employed in the treatment of human ectoparasitic infestations, primarily scabies caused by Sarcoptes scabiei and pediculosis caused by lice species such as Pediculus humanus capitis (head lice).[33] Oral formulations, dosed at 200 μg/kg body weight, are commonly used for scabies, with a standard regimen of two doses administered 7–14 days apart to target adult mites and newly hatched nymphs, especially in cases of crusted scabies or immunocompromised patients.[34] [35] This approach has demonstrated cure rates comparable to topical permethrin 5%, with clinical studies reporting mite clearance in over 90% of uncomplicated cases after the second dose.[36] [37] For crusted (Norwegian) scabies, involving hyperinfestation, higher cumulative doses (e.g., up to 400 μg/kg total across multiple administrations) combined with topical agents are recommended due to high mite burdens.[13] Although not FDA-approved specifically for scabies in the United States, ivermectin is endorsed by international guidelines such as those from the World Health Organization for mass treatment campaigns in endemic areas, reflecting its established efficacy despite off-label status.[38] [39] Ivermectin starts acting against scabies mites within 12–24 hours of the first dose. Patients often continue to experience itching for up to 1-2 weeks (or longer) even after mites die, due to lingering immune reaction and dead mite debris. New lesions may briefly appear in the first 72 hours in some cases. Symptom relief and full resolution typically occur within 1-4 weeks, with repeat dosing ensuring complete eradication. Topical ivermectin 1% lotion has shown equivalent efficacy to permethrin in randomized trials for uncomplicated scabies, with resolution of pruritus and lesions typically within 2–4 weeks, though oral administration offers advantages in compliance for widespread or institutional outbreaks.[36] Resistance concerns have emerged in some regions, prompting combination therapies, but recent evaluations confirm sustained mite clearance rates exceeding 85% with standard ivermectin regimens.[40] [41] In pediatric populations, oral ivermectin is generally restricted to children over 15 kg due to limited safety data, though pharmacokinetic modeling and small studies support its use at adjusted doses (e.g., 3 mg fixed for younger weights) with low adverse event rates.[42] [43] For head lice, topical ivermectin 0.5% lotion (Sklice) is FDA-approved for single-application treatment in patients aged 6 months and older, achieving lice eradication in approximately 78–95% of cases by paralyzing and killing nymphs and adults, though it may not fully eliminate unhatched eggs.[44] [45] Oral ivermectin serves as a second-line option for refractory infestations, with two 200 μg/kg doses 7 days apart outperforming malathion lotion in randomized trials, yielding superior cure rates (up to 95%) in difficult-to-treat scenarios.[46] [47] Guidelines from the American Academy of Pediatrics and Centers for Disease Control and Prevention recommend reserving oral use for cases resistant to topical pediculicides, emphasizing its role in preventing resistance escalation.[44] [48] Similar protocols apply to pubic lice (Pthirus pubis), where oral ivermectin is positioned as an alternative to topical agents like permethrin.[49] Topical ivermectin 1% cream (e.g., Soolantra) is approved for the treatment of inflammatory lesions of rosacea, often linked to Demodex mite populations. The recommended application involves a pea-sized amount to each affected facial area (forehead, chin, nose, cheeks) once daily as a thin layer, avoiding eyes, lips, mouth, and open wounds. Consistent use for at least 12 weeks is recommended for optimal results, with improvement potentially starting as early as 2 weeks in clinical studies, showing effects on inflammatory lesions of rosacea (including papules and bumps), and greater efficacy than vehicle starting at 4 weeks; one study reported a 27% reduction in bumps and blemishes after 2 weeks, increasing to about 65-75% reduction by week 12.[50][51] It exerts effects through anti-inflammatory activity and reduction of Demodex mites.[52][53] Clinical studies, including 40-week extension trials and up to 52 weeks of treatment in 519 subjects, showed no plasma accumulation of ivermectin, a stable safety profile, lower incidence of related adverse events compared to azelaic acid 15% gel, mild side effects (e.g., skin burning or irritation in ≤1% of patients), and no discontinuations due to adverse events in long-term ivermectin groups.[54][53] The FDA prescribing information supports use as directed without a specified maximum duration limit.[53] Across these applications, ivermectin's broad-spectrum action on glutamate-gated chloride channels in invertebrate nerves underpins its ectoparasicidal effects, with human trials consistently reporting minimal systemic absorption and adverse events limited to mild gastrointestinal upset or pruritus in under 5% of patients.[55][56] Veterinary Applications Common Uses in Animals Ivermectin is routinely administered to livestock such as cattle, swine, sheep, and horses to control internal parasites including gastrointestinal roundworms (e.g., Ostertagia spp., Cooperia spp.), lungworms (Dictyocaulus spp.), and external parasites like grubs (Hypoderma spp.), sucking lice, and mites.[57][58][59] A single low-volume injectable dose at 200 mcg/kg body weight effectively targets over 30 species and stages of these parasites in cattle and swine, reducing economic losses from parasitism in agriculture.[57][60] In companion animals, particularly dogs, ivermectin serves as a monthly preventive for heartworm disease caused by Dirofilaria immitis, typically at doses of 6 mcg/kg in products like Heartgard Plus, which also controls hookworms (Ancylostoma caninum) and roundworms (Toxocara canis, Toxascaris leonina).[61][62] It is primarily used for heartworm prevention, intestinal parasites, and certain mites (e.g., sarcoptic mange, ear mites, demodex); however, ivermectin has limited to no reliable efficacy against ticks in dogs and is not recommended or labeled for tick control. Studies show mixed results: some older research indicated it could cause brown dog ticks to drop off and die, but recent field studies report very low efficacy (e.g., 2.95% to 40.54% reduction in tick counts compared to >96% for afoxolaner), with emerging resistance in tick populations.[63] It is also used off-label or in combination for treating demodectic mange (Demodex spp.), sarcoptic mange (Sarcoptes scabiei), ear mites (Otodectes cynotis), and certain intestinal nematodes, with efficacy demonstrated at higher doses like 300-600 mcg/kg for mange over several weeks; however, it is not recommended for skin lesions after grooming, which are typically caused by bacterial infections such as post-grooming furunculosis (often due to Pseudomonas spp.) requiring antibiotics like fluoroquinolones, and its use for confirmed parasitic mite infestations requires veterinary diagnosis and guidance due to toxicity risks in breeds with MDR1 gene mutations, such as Collies.[64][65][66][67] In cats, ivermectin is primarily indicated for heartworm prevention at 24 μg/kg orally once monthly and for ectoparasites like ear mites; it is not commonly recommended as a primary dewormer for intestinal parasites (e.g., roundworms, hookworms), where other agents such as pyrantel or fenbendazole are preferred. While effective against some nematodes (except tapeworms), its use for routine intestinal deworming is off-label, lacks a standard dosage, and requires veterinary supervision due to a narrow safety margin; overdose can cause severe neurotoxicity (e.g., ataxia, blindness, coma). Large animal formulations should be avoided, and doses must be adjusted to minimize toxicity risks in sensitive individuals.[64][68] Formulations vary by species: pour-on or injectable for large ruminants to achieve systemic distribution against migrating larvae, oral chewables for dogs to ensure compliance in heartworm prophylaxis, and topical for ectoparasites in swine.[69][62] These uses stem from ivermectin's broad-spectrum activity against nematodes and arthropods, approved by the FDA for veterinary indications since the 1980s, contributing to improved animal health and productivity.[6][3] To minimize human exposure during administration to livestock (e.g., pour-on or injectable formulations for goats, cattle, etc.), users should wear protective gloves, long sleeves, and avoid direct skin contact. Product labels for veterinary ivermectin often advise immediate washing with soap and water if accidental skin contact occurs. Brief incidental exposure, such as small splashes or drips on intact skin, generally results in very limited dermal absorption and is not considered dangerous for healthy adults, with systemic levels remaining low compared to oral or large topical doses. Prompt washing reduces any potential uptake further. In contrast, prolonged or repeated exposure, especially on broken skin or under occlusion, can increase absorption and risk toxicity, as seen in rare cases of intentional misuse leading to severe neurological effects or fatality. Veterinary formulations are not intended for human use and may contain excipients or concentrations that heighten irritation or absorption risks upon contact. Impact on Agriculture and Livestock Ivermectin has significantly enhanced livestock productivity by controlling internal and external parasites in species such as cattle, sheep, goats, and swine, leading to improved weight gain, milk production, and overall herd health.[58][70] In beef cattle, treatment of cow herds has demonstrated increased economic returns through better calf performance and cow condition scores, as evidenced by field studies in North Dakota where ivermectin application correlated with higher productivity metrics.[71] For goats, experimental data from Bangladesh showed treated animals achieving an average live weight gain of 0.76 kg compared to 0.14 kg in untreated controls, underscoring direct benefits to growth efficiency.[72] The economic implications extend to reduced losses from parasitism, which can otherwise cost livestock operations millions annually; for instance, U.S. cattle producers face estimated annual losses of nearly $14 million from internal and external parasites alone.[73] Globally, the veterinary ivermectin market reached approximately $1.5 billion in 2023, reflecting its widespread adoption for preventing productivity declines in ruminants and swine by targeting over 30 parasite species and stages.[74][58] These gains stem from ivermectin's broad-spectrum efficacy against gastrointestinal nematodes, lungworms, lice, and mites, administered via injectable, pour-on, or oral formulations that minimize animal handling stress.[75][59] However, prolonged use has fostered anthelmintic resistance in gastrointestinal nematodes across cattle, sheep, and goats, with reports of ivermectin efficacy failures in Europe, including reduced clearance rates in Irish dairy farms and multi-drug resistance in U.S. sheep farms affecting up to 22% of Haemonchus contortus populations.[76][77][78] Resistance mechanisms, driven by selective pressure from frequent dosing, compromise long-term control and necessitate integrated management strategies like fecal egg count monitoring.[79] Additionally, ivermectin residues in cattle dung persist for weeks to months, disrupting dung beetle abundance and diversity, which impairs fecal degradation, nutrient recycling, and soil health in pastures—effects observed in both temperate and tropical settings.[80][81][82] These ecological repercussions may indirectly affect forage quality and long-term agricultural sustainability, though direct livestock productivity benefits have historically outweighed such concerns in intensive systems.[80] Safety and Adverse Effects Common and Serious Side Effects In therapeutic doses for approved human uses such as onchocerciasis and strongyloidiasis, ivermectin commonly induces mild, transient adverse effects, frequently linked to the Mazzotti reaction from dying parasites. These include pruritus (25.3% of reports), headache (13.9%), rash, myalgia, arthralgia, fever, and edema, typically peaking within 1-3 days post-dose and resolving without intervention.[83][84] Gastrointestinal symptoms such as nausea, diarrhea, vomiting, and abdominal pain occur in 1-10% of patients, alongside dizziness, fatigue, and somnolence.[85][86] Skin manifestations like urticaria or swelling may mimic or exacerbate underlying parasitic dermatitis.[87] Serious adverse effects are rare at standard doses (e.g., 150-200 mcg/kg) but include severe Mazzotti reactions with hypotension, tachycardia, lymphadenopathy, or ocular involvement in heavy onchocerciasis burdens.[83] In regions endemic for loiasis, ivermectin can precipitate encephalopathy, ataxia, seizures, or coma in individuals with high Loa loa microfilarial loads (>30,000 mf/mL), due to rapid parasite clearance overwhelming cerebral blood flow; such risks prompted WHO guidelines for pre-treatment screening in co-endemic areas.[88][84] In clinical studies for strongyloidiasis involving 109 patients treated with 170-200 mcg/kg ivermectin, drug-related adverse reactions included: asthenia/fatigue (0.9%), abdominal pain (0.9%), anorexia (0.9%), constipation (0.9%), diarrhea (1.8%), nausea (1.8%), vomiting (0.9%), dizziness (2.8%), somnolence (0.9%), vertigo (0.9%), tremor (0.9%), pruritus (2.8%), rash (0.9%), and urticaria (0.9%).[18] For onchocerciasis in trials with 963 patients treated with 100-200 mcg/kg, drug-related reactions in ≥1% included facial edema (1.2%), peripheral edema (3.2%), orthostatic hypotension (1.1%), and tachycardia (3.5%). Headache and myalgia occurred in <1%. Worsening of Mazzotti reactions in the first 4 days post-treatment included arthralgia/synovitis (9.3%), various lymph node enlargements and tenderness (up to 13.9%), pruritus (27.5%), skin involvement including edema, papular/pustular rash or urticaria (22.7%), and fever (22.6%).[18] These rates highlight that side effects are generally low in strongyloidiasis but higher in onchocerciasis due to the Mazzotti reaction from dying microfilariae. Overdose, often from veterinary products containing higher concentrations, leads to dose-dependent neurotoxicity via GABA receptor agonism, manifesting as confusion, tremors, hypotension, respiratory depression, and seizures; U.S. poison center data from 2021 reported over 1,400 exposures with 21% requiring hospitalization, though fatalities are exceptional with supportive care.[89][90] Liver enzyme elevations or leukopenia occur infrequently but warrant monitoring in prolonged regimens. In preclinical studies, ivermectin at 2.5 mg/kg reduced erythrocyte counts, hemoglobin concentration, and hematocrit in rabbits; no evidence exists of ivermectin causing hematocrit reduction, anemia, or erythrocytosis in humans, though rare (1%) increases in hemoglobin have been reported.[91][83] Overall, the drug's safety profile in approved indications remains favorable, with adverse event rates below 5% for severe outcomes in controlled trials.[83] Contraindications and Drug Interactions Ivermectin is contraindicated in patients with hypersensitivity to the active substance or any excipients in the formulation.[18][92] A major relative contraindication exists for individuals co-infected with Loa loa, particularly those with microfilarial densities exceeding 30,000 per milliliter of blood, as ivermectin treatment can trigger rapid microfilarial death leading to severe encephalopathy, coma, or death due to inflammatory responses in the central nervous system.[18][88][35] Safety and efficacy have not been established in pregnant women, where animal studies showed no teratogenicity but human data are limited, nor in lactating women, as ivermectin is excreted in low concentrations in breast milk; use requires weighing risks against benefits.[93][18] In pediatric patients weighing less than 15 kg, ivermectin is not recommended due to insufficient data on safety and dosing.[93][18] Ivermectin undergoes hepatic metabolism primarily via CYP3A4 enzymes and is a substrate for the P-glycoprotein (P-gp) efflux transporter, potentially leading to interactions with modulators of these pathways.[19][94] Concomitant administration with strong CYP3A4 inhibitors, such as ketoconazole or ritonavir, can elevate ivermectin plasma levels by reducing clearance, increasing the risk of neurotoxicity.[19] Similarly, P-gp inhibitors like cyclosporine may enhance ivermectin absorption and systemic exposure.[94] Case reports indicate potential interaction with warfarin, where ivermectin may potentiate anticoagulant effects, necessitating INR monitoring.[95] Concurrent use with alcohol can amplify central nervous system side effects, including dizziness and sedation, due to additive pharmacodynamic effects. No specific pharmacokinetic or pharmacodynamic interactions with opioids (such as oxycodone, hydrocodone, fentanyl, morphine, codeine, buprenorphine, methadone, or tramadol) are reported in major drug databases, which list 106 total interactions for ivermectin but none involving opioids; however, additive central nervous system effects may occur due to overlapping side effects like dizziness or drowsiness.[96] Overall, clinically significant interactions are infrequent at standard antiparasitic doses, but caution is advised in polypharmacy scenarios involving hepatic or transporter pathway drugs.[19] Toxicity in Overdose Ivermectin toxicity manifests primarily through central nervous system depression when ingested in doses exceeding therapeutic levels, typically above 0.2 mg/kg in humans, often resulting from misuse of veterinary formulations such as horse paste, containing higher concentrations unsuitable for human consumption. These animal preparations are highly dangerous for human use, being toxic and capable of causing severe poisonings with potential lasting neurological damage. Applying veterinary ivermectin formulations topically to human skin carries specific risks, including lack of sterility for human application, high concentrations that can cause severe skin irritation or chemical burns, and potential for systemic absorption leading to neurological issues, seizures, or overdose. Such self-treatment may also delay professional diagnosis of suspicious skin lesions, such as skin cancer, with potentially life-threatening consequences.[97] Neurological symptoms predominate, including ataxia, dizziness, tremors, confusion, mydriasis, and hypotension, progressing to seizures, coma, and respiratory failure in severe cases due to enhanced GABAergic inhibition and glutamate channel disruption at the blood-brain barrier when plasma levels overwhelm P-glycoprotein efflux.[98] Gastrointestinal effects such as nausea, vomiting, and diarrhea may occur initially but are less prominent than neurotoxicity.[99] Overdose cases surged in 2021, with U.S. poison centers reporting over 20-fold increases in exposures, largely from self-administration of animal products for unapproved COVID-19 prevention or treatment, leading to hospitalizations for supportive care including activated charcoal, intravenous fluids, benzodiazepines for seizures, and mechanical ventilation if needed.[89] Recovery is common with prompt intervention, as ivermectin's half-life of 18 hours allows for gradual clearance, though veterinary preparations exacerbate risks due to excipients and dosing errors yielding effective intakes up to 100 times therapeutic doses.[100] Human formulations, by contrast, incorporate lower potencies and safer excipients, reducing overdose severity at equivalent volumes.[99] Misuse of veterinary ivermectin formulations (e.g., horse pastes, injectables) has led to severe toxicity, with symptoms including intense gastrointestinal upset (nausea, vomiting, watery diarrhea), neurotoxicity (confusion, ataxia, seizures, coma), hypotension, and respiratory issues. Case series from 2021 reported hospitalizations for such effects, often from high doses intended for large animals. Poison control centers noted surges in exposures during the COVID-19 pandemic, with rapid onset of severe symptoms due to concentrated formulations and unapproved excipients. [89] [101] Fatalities from ivermectin overdose remain rare overall, but additional documented cases exist beyond those already noted. A 2022 French pharmacovigilance study of adverse drug reactions associated with ivermectin use (primarily during the COVID-19 period) identified 6 deaths among 35 serious cases where ivermectin was reported as the single suspect drug. These deaths involved neurologic disorders (including coma), respiratory issues, gastrointestinal complications, and cardiac arrest. In the United States, New Mexico health officials reported two suspected deaths from ivermectin poisoning in 2021, linked to self-medication attempts to treat or prevent COVID-19 using veterinary formulations. Colorado has recorded at least two deaths mentioning or attributed to ivermectin toxicity since 2020 (with none from 2010-2020), including a 2023 case and a more recent 2025 fatality of a 74-year-old woman ruled as "ivermectin toxicity" by the Douglas County coroner. A notable 2025 case report detailed the first documented fatal transdermal ivermectin poisoning: an adult woman applied a 1% veterinary dermal solution approximately 2 g/day for one month, resulting in a plasma concentration of 27 ng/mL. Initial gastrointestinal symptoms progressed to severe diffuse cerebral edema, intracranial hypertension, and cerebral circulatory arrest, leading to death despite intensive interventions including hemoperfusion, osmotherapy, and cardiorespiratory support. These cases underscore that while most overdoses are survivable with prompt care, extreme exposures—especially from veterinary products or non-oral routes—can prove lethal, often involving neurotoxicity from blood-brain barrier penetration. High-dose tolerability and pharmacokinetics High-dose studies in healthy volunteers and other indications have demonstrated ivermectin tolerability at levels exceeding approved antiparasitic doses. Single doses up to 120 mg (~2 mg/kg) or 600 µg/kg daily for 6 days produced mostly mild, transient effects (headache, dizziness, nausea, rash, visual disturbances) similar to placebo, with no serious CNS toxicity observed. Repeated dosing examples include up to 1.6 mg/kg subcutaneously twice weekly for 12 weeks with acceptable safety. Plasma peaks at ~2 mg/kg approach lower preclinical ranges, though anticancer effects often require higher in vitro levels. Overdose risks (neurotoxicity) primarily associate with massive veterinary exposures or barrier compromise, not clinical high doses. These data support safety in exploratory regimens (e.g., 0.4–1 mg/kg intermittent in cancer combinations), though no oncology-specific MTD established. Lactation and Breastfeeding Safety Limited data indicate that ivermectin is poorly excreted into breast milk after oral administration. After typical single doses (150–200 mcg/kg), milk concentrations average around 9–10 mcg/L, with peaks up to 15–21 mcg/L. The relative infant dose is estimated at 0.7–0.98% of the maternal weight-adjusted dose, resulting in negligible exposure for exclusively breastfed infants. No adverse effects are expected in breastfed infants over 7 days of age based on available studies. For topical ivermectin, systemic absorption is lower, and it is sometimes considered a treatment of choice for scabies in nursing mothers, provided application avoids the breas